Everolimus is an effective drug used for the treatment of certain types of cancer such as Breast cancer, PNT and Renal cell carcinoma. However, it may not possibly be as effective in some patient as it is in others. It has been seen to have led to adverse reactions in some patients, due to which its use had to be terminated. Hence in such cases, Afinitor Alternatives may be administered to the patients in order to avoid adverse effects. Following are the different drugs that prove to be very effective Afinitor Alternatives:
As far as the treatment of RCC is considered, Nexavar marketed under the coalition of Bayer and Onyx, is one of the potent rivals of Everolimus. Although the mechanism of action is principally different; yet both work to bring the tumour growth to a halt and hence improve or, at least maintain the patientâ€™s health.
Votrient is another Afinitor alternative marketed by the pharmaceutical company, GlaxoSmithKline. The drug works as a tyrosine kinase inhibitor and exhibits a strong antitumor activity in addition to its anti-angiogenetic action.
After sutent â€“ the first line treatment of RCC â€“ Pfizer has launched another drug for RCC under the trade name of Inlyta. The drug has been demonstrated to be more effective than Bayerâ€™s Nexavar through trials.
Torisel is yet another alternative of Everolimus marketed by Wyeth pharmaceuticals.
Sutent, manufactured by Pfizer, is a drug indicated for RCC, GIST and PNT. It works as a tyrosine kinase inhibitor and thus exhibits strong anti-tumour activity. Afinitor and Sutent both are very effective drugs for specific types of cancer and one may outshine the other in one aspect or the other. However, in case of pancreatic neuro-endocrinal tumours both the drugs metaphorically stand against each other. Establishing a comparison between Afinitor and Sutent is to some extent difficult, since there are practically, very minute parameters to bring in to consideration in order to compare Afinitor and Sutent. However, a survey demonstrates that the patients on Everolimus showed more occurrences of seizures as compared to those on sutent. In addition, a phase III study, consisting of two trials (one on the efficacy of sutent and other on that of everolimus) also showed the mean progression free survival (PFS) of PNT patients on sutent to be 11.4 months while the PFS of patients on Everolimus turned out to be 11 months. Although, the two figures are very close, yet for a patient fighting against fatality; even a small division of time may matter a great deal.